Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics

A genome-wide association (GWA) study of treatment outcomes (response and remission) of selective serotonin reuptake inhibitors (SSRIs) was conducted using 529 subjects with major depressive disorder (MDD). While no SNP associations reached the genome-wide level of significance, 14 SNPs of interest...

Full description

Bibliographic Details
Main Authors: Ji, Yuan, Biernacka, Joanna M., Hebbring, Scott, Chai, Yubo, Jenkins, Gregory D., Batzler, Anthony, Snyder, Karen A., Drews, Maureen S., Desta, Zeruesenay, Flockhart, David, Mushiroda, Taisei, Kubo, Michiaki, Nakamura, Yusuke, Kamatani, Naoyuki, Schaid, Daniel, Weinshilboum, Richard M., Mrazek, David A.
Format: Online
Language:English
Published: 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941038/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941038/

Similar Items